I. Drug Name

Generic Name: Ponatinib Tablets

English Name: Ponatinib

Trade Names: Iclusig, PONADX

Dosage Form: Oral Tablets

Specification: 15 mg per tablet; 45 mg per tablet; 30 tablets per box

Manufacturer: Laos Great Bear Pharmaceutical Co., Ltd.

Regulatory Approval Numbers: 11 L1248/24; 11 L1249/24

II. Pharmacological Actions

Pharmacological Classification: Tyrosine Kinase Inhibitor (TKI)

Mechanism of Action: Ponatinib is a potent, orally active, multi-targeted tyrosine kinase inhibitor.

Its primary target is BCR-ABL, the oncogenic driver gene responsible for Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).

A unique feature of Ponatinib is that its molecular structure is designed to effectively inhibit the T315I-mutant form of BCR-ABL—a mutation that confers resistance to all other currently marketed BCR-ABL TKIs.

Additionally, it inhibits multiple other targets, including VEGFR, PDGFR, FGFR, EPH, members of the SRC family, KIT, RET, TIE2, and FLT3.

III. Indications

Ponatinib is indicated for the treatment of the following adult patients:

1. Chronic Myeloid Leukemia (CML):

Patients with CML in the chronic, accelerated, or blast phase who are resistant to or intolerant of prior TKI therapy.

It is particularly indicated for patients with CML harboring the T315I mutation.

2. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL):

Patients who are resistant to or intolerant of prior TKI therapy.

It is particularly indicated for patients with Ph+ ALL harboring the T315I mutation.

IV. Dosage and Administration

Recommended Starting Dose: 45 mg, once daily, taken orally.

Dose Adjustment:

Upon achieving remission or in the event of adverse reactions, consideration should be given to reducing the dose to 15 mg or 30 mg, once daily. Current clinical practice tends to favor the use of lower starting doses (e.g., 30 mg or 15 mg) to balance efficacy and safety, particularly in patients with chronic-phase CML.

Administration:

Swallow tablets whole; may be taken with or without food.

If a dose is missed, do not take a double dose to make up for it; instead, wait until the next scheduled time to take the regular dose.

V. Contraindications

Patients with a history of severe hypersensitivity to ponatinib or to any of the excipients.

VI. Warnings and Precautions ([Boxed Warning])

Ponatinib carries the following [Boxed Warning], representing its most serious safety alerts:

1. Arterial Occlusion:

Fatal and life-threatening arterial occlusive events may occur, including myocardial infarction, stroke, cerebral vascular stenosis, and arterial stenosis requiring urgent revascularization.

These events may occur at any time during treatment, even in patients without cardiovascular risk factors.

2. Venous Thromboembolism:

Fatal and life-threatening venous thromboembolic events may occur, such as deep vein thrombosis, pulmonary embolism, retinal vein occlusion, and portal vein thrombosis.

3. Heart Failure:

Fatal and life-threatening heart failure may occur, including left ventricular dysfunction.

4. Hepatotoxicity:

Severe hepatotoxicity, liver failure, and even death may occur.

Monitoring and Management:

Assess cardiovascular risk prior to initiating treatment and periodically during treatment.

Closely monitor patients for signs and symptoms of arterial/venous thrombosis, heart failure, and hepatotoxicity.

Depending on the severity, treatment may require interruption, dose reduction, or permanent discontinuation.

VII. Other Important Warnings and Precautions

1. Hypertension: Hypertension may occur or worsen. Blood pressure should be monitored and controlled during treatment.

2. Pancreatitis: Elevated serum lipase levels and pancreatitis may occur. Monitor serum lipase levels prior to initiating treatment and periodically during treatment.

3. Hemorrhage: Serious hemorrhagic events may occur. Treatment should be interrupted in patients experiencing serious hemorrhage. 4. Fluid Retention: Pleural effusion, pericardial effusion, cardiac tamponade, and generalized edema may occur.

5. Arrhythmias: Bradycardia, atrial fibrillation, atrial flutter, and other arrhythmias may occur.

6. Tumor Lysis Syndrome (TLS): TLS may occur in patients with a high tumor burden.

7. Impaired Wound Healing: May interfere with wound healing. Discontinue use at least 1 week prior to elective surgery.

8. Embryo-Fetal Toxicity: May cause harm to the fetus when administered to pregnant women. Effective contraception must be used.

VIII. Adverse Reactions

Very Common (>10%) Serious and/or Major Adverse Reactions:

Cardiovascular: Hypertension, arterial occlusive disease.

Skin and Subcutaneous Tissue: Rash, dry skin.

Gastrointestinal: Abdominal pain, constipation, pancreatitis (including elevated serum lipase), nausea, diarrhea.

General Disorders: Fatigue, arthralgia, headache, pyrexia, peripheral edema, fluid retention.

Hematologic and Lymphatic: Thrombocytopenia, anemia, neutropenia.

Metabolism and Nutrition: Decreased appetite.

Musculoskeletal: Myalgia, back pain.

Nervous System: Peripheral neuropathy, insomnia.

Respiratory: Cough, dyspnea, nasopharyngitis, pneumonia.

IX. Drug Interactions

Strong CYP3A Inhibitors (e.g., clarithromycin, itraconazole, ritonavir):

Co-administration increases ponatinib plasma concentrations, thereby increasing the risk of adverse reactions.

Avoid co-administration. If co-administration is unavoidable, consider reducing the dose of ponatinib.

Strong CYP3A Inducers (e.g., rifampin, carbamazepine, St. John's wort):

Co-administration decreases ponatinib plasma concentrations, potentially compromising efficacy.

Avoid co-administration.

X. Use in Specific Populations

Pregnant Women: May cause fetal harm. Advise pregnant women of the potential risk to the fetus. Lactation: It is recommended to discontinue breastfeeding during treatment and for 6 days following the last dose.

Pediatric Patients: Safety and efficacy have not been established.

Geriatric Patients: May be more susceptible to adverse reactions.

Patients with Hepatic/Renal Impairment:

Hepatic Impairment: No dose adjustment is required for patients with mild to moderate hepatic impairment. For patients with severe hepatic impairment, the recommended starting dose is 30 mg once daily.

Renal Impairment: No dose adjustment is required for patients with mild to moderate renal impairment. For patients with severe renal impairment or those requiring dialysis, the recommended starting dose is 30 mg once daily.

XI. Overdosage

Symptoms: Expected symptoms consist of an exacerbation of known adverse reactions.

Management: The drug should be discontinued immediately; supportive care and symptomatic treatment should be initiated.

XII. Patient Counseling Information

1. Understanding [Boxed Warning] Risks: Fully understand the serious risks associated with arterial/venous thrombosis, heart failure, and hepatotoxicity, and immediately report any related symptoms (e.g., chest pain, difficulty breathing, limb weakness, vision changes, etc.).

2. Strict Adherence to Medical Advice: Do not adjust the dosage on your own.

3. Regular Monitoring: Understand the critical importance of undergoing regular cardiovascular assessments, as well as monitoring of liver function, serum lipase levels, and complete blood counts.

4. Contraception Requirements: Patients of reproductive potential must understand and strictly adhere to contraception requirements.

5. Inform Your Doctor: Inform your doctor of your complete medical history and current health status, particularly any history of cardiovascular disease.

Final Emphasis: The use of ponatinib involves significant risks and must be strictly managed by a physician experienced in the treatment of leukemia. Please be sure to follow the specific instructions provided by your treating physician.